Vertex Pharmaceuticals was founded in 1989 and operates in Boston, United States. The company engages in the sector 'Pharmaceuticals, Medicinal Chemical & Botanical Products' (ISIC: 2100).

Vertex Pharmaceuticals Inc. closed $45.72 below its 52-week high ($510.64), which the company achieved on August 1st.

The 12-month price targets, analyzed by analysts, offer insights with an average target of $508.38, a high estimate of ...

Vertex Pharmaceuticals (VRTX) has recently been on Zacks.com's list of the most searched stocks. Therefore, you might want to consider some of the key factors that could influence the stock's ...

In a report released today, Brian Abrahams from RBC Capital maintained a Hold rating on Vertex Pharmaceuticals (VRTX – Research Report), ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

According to Benzinga Pro, Vertex Pharmaceuticals's peer group average for short interest as a percentage of float is 6.15%, ...

Truist Financial analyst Joon Lee assigned a Buy rating to Vertex Pharmaceuticals (VRTX – Research Report) today and set a price target of $550.00. The company’s shares closed last Friday at ...

Vertex Pharmaceuticals, Inc. is a global biotechnology company, which engages in the business of discovering, developing, manufacturing, and commercializing small molecule drugs for patients with ...

This was the stock's second consecutive day of losses.